Prostate Cancer

PCa-specific mortality not affected by comorbidityComorbidity does not affect prostate cancer-specific mortality, according to authors of a large prospective observational study of men in Sweden, published in the Journal of Clinical Oncology (2017; 35:3566-74).
BMI predicts post-RP metastasis, prostate cancer mortalityBody mass index is an independent predictor of metastasis and prostate cancer mortality after radical prostatectomy, according to results from a large, long-term single-institution study.
Active surveillance linked with moderate anxietyMen undergoing active surveillance for prostate cancer experienced levels of anxiety that were moderate, but that decreased over time, according to results of a large, prospective cohort study presented at the 2017 Society of Urologic Oncology annual meeting in Washington.
Challenges remain for active surveillance in low-risk PCa“Active surveillance continues to gain traction as a management strategy for low-risk prostate cancer in the United States. However, barriers still exist and challenges remain for both the treating urologist and the patient,” writes J. Brantley Thrasher, MD.
Top 9 peer-reviewed prostate cancer papers of 2017Multiparametric MRI, USPSTF’s updated PSA screening recommendation, and the landmark STAMPEDE and LATITUDE trials were among this year’s highlights in the peer-reviewed literature for prostate cancer, according to Leonard G. Gomella, MD; Stacy Loeb, MD, MS; and J. Brantley Thrasher, MD.
Study: Active surveillance uptake remains lowThe overall use of active surveillance in men with low-risk prostate cancer is 14.2%, according to an examination of the National Cancer Data Base.
Tissue-based PCa assays not robust to multifocalityTissue-based prognostic biomarker assays for prostate cancer are not robust to tumor multifocality and heterogeneity, according to research presented at the American Society of Clinical Oncology annual meeting in Chicago.
How to estimate life expectancy in men with localized prostate CaWhile no resource is perfect, it is worthwhile to familiarize yourself with some contemporary methodology and predictive tools to help determine life expectancy in localized prostate cancer patients.
AUA 2017: A small-town plumber’s 10 can’t-miss sessionsIn preparation for the AUA annual meeting in May, urologist Henry Rosevear, MD, shares the 10 sessions he’s looking forward to the most.
Post-RT proctitis less likely in ACE inhibitor usersHigh-grade proctitis after radical radiation therapy with neoadjuvant or adjuvant hormonal therapy is significantly less likely in patients taking angiotensin-converting-enzyme inhibitors.